<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801788</url>
  </required_header>
  <id_info>
    <org_study_id>OC-EG-001</org_study_id>
    <nct_id>NCT00801788</nct_id>
  </id_info>
  <brief_title>Single Dose Pharmacokinetics of Egalet® Oxycodone</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egalet Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Egalet Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacokinetic profile of different Egalet®
      oxycodone formulations and compare to a marketed oxycodone product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate pharmacokinetics of Egalet® oxycodone. AUC0-t, AUC0-inf, Cmax, Residual Area, Tmax, T½ el,Kel,AUC 0-12 and AUC 0-24.</measure>
    <time_frame>Single-dose evaluation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability of Egalet® oxycodone. Hematology, biochemistry, urinalysis, vital signs (including pulse oximetry), and adverse event monitoring.</measure>
    <time_frame>Single-dose evaluation</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Egalet® oxycodone Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egalet® oxycodone Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Egalet® oxycodone Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single Dose Administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone hydrochloride</intervention_name>
    <description>Extended release tablet</description>
    <arm_group_label>Egalet® oxycodone Treatment A</arm_group_label>
    <arm_group_label>Egalet® oxycodone Treatment B</arm_group_label>
    <arm_group_label>Egalet® oxycodone Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone hydrochloride</intervention_name>
    <description>Extended release tablet</description>
    <arm_group_label>Active comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          -  ≥18 years and ≤55 years

          -  Non-smoker

          -  BMI ≥18.0 and ≤30.0

        Main exclusion criteria:

          -  Any clinically significant abnormality or abnormal laboratory test results found
             during medical screening

          -  History of allergic reactions to opioids or other related drugs

          -  History of significant alcohol abuse or drug abuse

          -  Use of any drugs known to inhibit hepatic drug metabolism

          -  Pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Andersen, M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>Egalet A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2008</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

